Mount Yale Investment Advisors LLC Sells 423 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mount Yale Investment Advisors LLC cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,559 shares of the medical equipment provider’s stock after selling 423 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Hologic were worth $636,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Massmutual Trust Co. FSB ADV increased its holdings in Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares in the last quarter. Graypoint LLC grew its holdings in Hologic by 3.9% during the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after buying an additional 147 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in Hologic by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after buying an additional 165 shares in the last quarter. Parallel Advisors LLC raised its position in Hologic by 11.5% in the 4th quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 189 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in Hologic by 0.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock valued at $2,425,000 after acquiring an additional 192 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent analyst reports. Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 18th. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, September 17th. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Finally, Evercore ISI increased their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Insider Transactions at Hologic

In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock worth $1,469,973 over the last quarter. Corporate insiders own 1.75% of the company’s stock.

Hologic Price Performance

Hologic stock opened at $81.46 on Tuesday. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The business’s 50 day simple moving average is $80.90 and its 200 day simple moving average is $77.17. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a market cap of $19.01 billion, a price-to-earnings ratio of 41.56, a PEG ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the company earned $0.93 EPS. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.09 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.